The above results suggest that NRF2 negatively regulates PHKG2 expression, and targeted inhibition of NRF2 can promote ferroptosis after radiotherapy by upregulating PHKG2, thereby reversing NSCLC radioresistance. This evidence concerns the gene PHKG2 and non-small cell lung carcinoma.